Friday, February 24, 2017

Gainers & Losers Of The Day: CEMP, IPCI, OREX, RNVA, ARGS...

Cempra Inc.'s oral Fusidic acid has met the primary endpoint in a phase III study of ABSSSI.

from RTT - Biotech http://ift.tt/2l9qRbr
via IFTTT

No comments:

Post a Comment